Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871936 · ClinicalTrials.gov registry record · Phase 2
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
A Phase 2 study of Type 2 Diabetes, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 12
- Study locations
NCT00871936: Completed Phase 2 study of Type 2 Diabetes, sponsored by Response Pharmaceuticals.
NCT00871936 is a Phase 2 study of Type 2 Diabetes that has completed, run by Response Pharmaceuticals. The registered enrollment target is 82 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00871936, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Metformin
- DRUG SLx-4090
Study Locations (12)
California
- - Anaheim
- - Burbank
- - Los Angeles
- - Los Angeles
North Carolina
- - Charlotte
- - Hickory
- - Winston-Salem
Florida
- - West Palm Beach
Illinois
- - Addison
Maine
- - Auburn
South Carolina
- - Greenville
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00871936 record still lists
NCT00871936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00871936 lists 12 locations in 7 states (California, North Carolina, Florida).
Frequently Asked Questions
What is clinical trial NCT00871936 about?
NCT00871936 is a clinical study titled "A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes". The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
What is the current status of trial NCT00871936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2009-04. Estimated completion is 2009-10.
What conditions does trial NCT00871936 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00871936?
The interventions under investigation include: Placebo (OTHER), Metformin (DRUG), SLx-4090 (DRUG).
Who is sponsoring clinical trial NCT00871936?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00871936 being conducted?
This trial has 12 study locations across California, Florida, Illinois, Maine, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00871936's enrollment target sits among peer trials
82 174th of 327 higher than 154 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia